Topic

Pompe disease

A collection of 2 issues

Sanofi Ends Maze Licensing Deal Over FTC Concerns

Sanofi has terminated its global licensing agreement with Maze Therapeutics for Pompe disease treatment, citing issues related to FTC regulations.

Maze and Shionogi Collaborate on Pompe Disease Program

Maze Therapeutics partners with Shionogi to develop a new program targeting Pompe disease. Explore innovative treatments and advancements in genetic disorders.